ALZpath Press Releases
ALZpath Named 2025 BRONZE Edison Award Winner for its Proprietary pTau217 Antibody, a Key Biomarker Driving Blood-Based Alzheimer’s Disease Diagnostics
April 7th, 2025
Data Showcasing ALZpath’s Proprietary pTau217 Antibody at AD/PD™ 2025 Demonstrates High Rate of Reliability and Scalability for Alzheimer’s Disease Research and Diagnosis
April 1st, 2025
ALZpath Adds Biotech Veteran to Board of Directors and Names Prominent Global Researcher as Distinguished Scientific Advisor
March 25th, 2025
ALZpath Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025
March 18th, 2025
Bio-Techne and ALZpath Announce Strategic Partnership to Advance Neurodegenerative Disease Research
November 18th, 2024
ALZpath Proprietary pTau217 Antibody Named to TIME’S List of the Best Inventions of 2024
October 30th, 2024
New Data Presented at AAIC 2024 Demonstrates High Accuracy of Blood Tests Incorporating ALZpath Proprietary pTau217 Antibody for Alzheimer’s Disease Diagnosis
July 29th, 2024
ALZpath Signs Licensing Agreement with Beckman Coulter Diagnostics to Provide Proprietary pTau217 Antibody to Develop a Diagnostic Blood Test for Alzheimer’s Disease
July 15th, 2024
ALZpath Announces Appointment of Chad Holland as President and Chief Executive Officer
July 9th, 2024
ALZpath Partners with Roche to Provide pTau217 Antibody for Alzheimer's Diagnostic Blood Test
June 10th, 2024
Alamar Biosciences and ALZpath, Inc. Announce Strategic Supply Agreement for pTau217 Antibody to Advance Alzheimer’s Disease Research
February 29th, 2024
New Study in JAMA Affirms High Diagnostic Accuracy of ALZpath's pTau217 Test
JANUARY 22, 2024
ALZpath Announces Partnership with ADDF for Clinical Alzheimer's Diagnostic Launch
JULY 18, 2023
